Treatment-related myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (AML) in children with cancer: A single-center experience

Int J Immunopathol Pharmacol. 2016 Dec;29(4):729-730. doi: 10.1177/0394632016670667. Epub 2016 Sep 19.

Abstract

Treatment-related myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (AML) is a devastating early or late complication of treatment for childhood cancer related with a significant morbidity and mortality. We retrospectively studied survivors of childhood cancer. Overall, 287 patients were recorded in the databases and we identified three (1.04%) with t-MDS. The primary cancer diagnoses were Langerhans cell histiocytosis (one patient) and acute lymphoblastic leukemia (ALL; two patients). The mean age of patients was 12.1 years. All patients had received systemic antifungal treatment for invasive pulmonary aspergillosis successfully treated with voriconazole and liposomal amphotericin B before diagnosis of t-MDS. Two patients (66%) remain alive after a median follow-up period of 3.5 years.

Keywords: Childhood; treatment-related myelodysplastic syndromes.

Publication types

  • Letter

MeSH terms

  • Amphotericin B / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Child
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Myelodysplastic Syndromes / chemically induced*
  • Neoplasms, Second Primary / drug therapy*
  • Retrospective Studies
  • Voriconazole / administration & dosage

Substances

  • liposomal amphotericin B
  • Amphotericin B
  • Voriconazole